Galactose-deficient immunoglobulin A1 (Gd-IgA1)

Galactose-deficient immunoglobulin A1 (Gd-IgA1) is a form of the IgA1 immunoglobulin in which the O-linked glycans in the hinge region lack galactose, resulting in terminal N-acetylgalactosamine or sialylated N-acetylgalactosamine residues[1][2]. This aberrant glycosylation exposes novel antigenic determinants, facilitating the formation of autoantibodies and immune complexes. These complexes deposit in the renal mesangium, triggering inflammation and tissue injury, and serving as the central effector in the pathogenesis of IgA nephropathy. Serum and urine levels of Gd-IgA1 correlate with disease severity and progression, and their measurement is increasingly used in diagnosis and prognosis[2][4][5]. KM55 monoclonal antibody staining is commonly employed for the detection of Gd-IgA1 deposits in kidney tissue[5]. No approved drugs directly target Gd-IgA1, though several therapeutic strategies are under research. Major safety concerns center on balancing immunosuppression without compromising normal IgA-mediated mucosal immunity.

Other names

Galactose-deficient IgA1Gd-IgA1Aberrantly glycosylated IgA1Hypogalactosylated IgA1

Experimental approaches include: Reduction of Gd-IgA1 production by targeting glycosylation pathways or B-cells; Blocking Gd-IgA1-containing immune complex deposition; Immunosuppression to reduce secondary immune activation.